Use: Labeled indications
- Treatment of the following infections caused by susceptible isolates of the designated microorganisms in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved
- Respiratory tract infections
- Urinary tract infections
- Skin and skin structure infections
- Biliary tract infections
- Bone and joint infections
- Genital infections
- Septicemia
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Cefazolin for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for: Treatment of the following infections caused by susceptible isolates of the designated microorganisms in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved: (1) Respiratory tract infections (1.1) Urinary tract infections (1.2) Skin and skin structure infections (1.3) Biliary tract infections (1.4) Bone and joint infections (1.5) Genital infections (1.6) Septicemia (1.7) Endocarditis (1.8) Perioperative prophylaxis in adults and pediatric patients aged 10 to 17 years old for whom appropriate dosing with this formulation can be achieved (1.9) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and Dextrose Injection and other antibacterial drugs, Cefazolin for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.10). 1.1 Respiratory Tract Infections Cefazolin for Injection and Dextrose Injection is indicated for the treatment of respiratory tract infections due to Streptococcus pneumoniae, Staphylococcus aureus and Streptococcus pyogenes in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2.1, 2.2, 2.4, 2.5) and Use in Specific Populations (8.4)].
Limitations of Use Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection and Dextrose Injection is indicated for the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. 1.2 Urinary Tract Infections Cefazolin for Injection and Dextrose Injection is indicated for the treatment of urinary tract infections due to Escherichia coli, and Proteus mirabilis in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2.1, 2.2, 2.4, 2.5) and Use in Specific Populations (8.4)]. 1.3 Skin and Skin Structure Infections Cefazolin for Injection and Dextrose Injection is indicated for the treatment of skin and skin structure infections due to S. aureus, S. pyogenes, and Streptococcus agalactiae in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2.1, 2.2, 2.4, 2.5) and Use in Specific Populations (8.4)]. 1.4 Biliary Tract Infections Cefazolin for Injection and Dextrose Injection is indicated for the treatment of biliary infections due to E. coli, various isolates of streptococci, P. mirabilis, and S. aureus in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2.1, 2.2, 2.4, 2.5) and Use in Specific Populations (8.4)]. 1.5 Bone and Joint Infections Cefazolin for Injection and Dextrose Injection is indicated for the treatment of bone and joint infections due to S. aureus in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2.1, 2.2, 2.4, 2.5) and Use in Specific Populations (8.4)]. 1.6 Genital Infections Cefazolin for Injection and Dextrose Injection is indicated for the treatment of genital infections due to E. coli, and P. mirabilis in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2.1, 2.2, 2.4, 2.5) and Use in Specific Populations (8.4)]. 1.7 Septicemia Cefazolin for Injection and Dextrose Injection is indicated for the treatment of septicemia due to S. pneumoniae, S. aureus, P. mirabilis, and E. coli in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2.1, 2.2, 2.4, 2.5) and Use in Specific Populations (8.4)]. 1.8 Endocarditis Cefazolin for Injection and Dextrose Injection is indicated for the treatment of endocarditis due to S. aureus and S. pyogenes in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2.1, 2.2, 2.4, 2.5) and Use in Specific Populations (8.4)]. 1.9 Perioperative Prophylaxis Cefazolin for Injection and Dextrose Injection is indicated for perioperative prophylaxis in adults and pediatric patients aged 10 to 17 years old for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2.1, 2.3, 2.4, 2.5) and Use in Specific Populations (8.4)].
The perioperative use of Cefazolin for Injection and Dextrose Injection is indicated in adult and pediatric (aged 10 to 17 years old) surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for Injection and Dextrose Injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). 1.10 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and Dextrose Injection and other antibacterial drugs, Cefazolin for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
- Immediate hypersensitivity to cefazolin, cephalosporins, penicillins or other beta-lactams
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) 4.1 Hypersensitivity to Cefazolin or the Cephalosporin Class of Antibacterial Drugs, Penicillins, or Other Beta-lactams Cefazolin for Injection and Dextrose Injection is contraindicated in patients who have a history of immediate hypersensitivity reactions (e.g., anaphylaxis, serious skin reactions) to cefazolin or the cephalosporin class of antibacterial drugs, penicillins, or other beta-lactams [see Warnings and Precautions (5.1)].
Dosing: Adult
- Moderate to severe infections: 500 mg to 1 g IV every 6 to 8 hours
- Mild infections (susceptible gram-positive cocci): 250 to 500 mg every 8 hours
- Acute uncomplicated urinary tract infection: 1 g every 12 hours
- Pneumococcal pneumonia: 500 mg every 12 hours
- Severe infections (endocarditis, septicemia): 1 to 1.5 g every 6 hours
- Perioperative prophylaxis: 1 to 2 g (3 g if 120 kg or more) 30 to 60 minutes before incision; 500 mg to 1 g during long surgery and every 6 to 8 hours for 24 hours after
- CrCl below 55 mL/min: 35–54: usual dose every 8 hours or longer; 11–34: half dose every 12 hours; 10 or less: half dose every 18 to 24 hours
- If a dose of Cefazolin for Injection and Dextrose Injection is required that does not equal 1 gram, 2 grams or 3 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered. (2.1)
- For intravenous use only administered over approximately 30 minutes. (2.1)
- Recommended Dosing Schedule in Adult Patients with CLcr Greater Than or Equal To 55 mL/min. (2.1, 2.2 and 2.3) Site and Type of Infection Dose Frequency Moderate to severe infections 500 milligram (mg) to 1 gram every 6 to 8 hours Mild infections caused by susceptible gram-positive cocci 250 mg to 500 mg every 8 hours Acute, uncomplicated urinary tract infections 1 gram every 12 hours Pneumococcal pneumonia 500 mg every 12 hours Severe, life-threatening infections (e.g., endocarditis, septicemia) In rare instances, doses of up to 12 grams of cefazolin per day have been used. 1 gram to 1.5 grams every 6 hours Perioperative prophylaxis less than 120 kg: 1 gram to 2 grams 1/2 to 1 hour prior to start of surgery greater than or equal to 120 kg: 3 grams 500 mg to 1 gram additional dose during lengthy operative procedures 500 mg to 1 gram every 6 to 8 hours for 24 hours postoperatively Recommended Dosing Schedule in Pediatric Patients with CLcr Greater than or Equal to 70 mL/min. (2.1, 2.2, and 2.3) Site and Type of Infection Dose Frequency Moderate to severe infections …
2.1 Important Administration Instructions
2.1 Important Administration Instructions If a dose of Cefazolin for Injection and Dextrose Injection is required that does not equal 1 gram, 2 grams, or 3 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered. Administer Cefazolin for Injection and Dextrose Injection intravenously over approximately 30 minutes.
2.2 Dosage for the Treatment of Infections
2.2 Dosage for the Treatment of Infections D osage for the Treatment of Infections in Adults with Creatinine Clearance (CLcr) Equal to 55 mL/min or Greater The recommended adult dosages for the treatment of infections [see Indications and Usage (1.1 to 1.8)] are outlined in Table 1 below. Administer Cefazolin for Injection and Dextrose Injection intravenously over approximately 30 minutes.
Table 1: Recommended Dosage in Adult Patients with CLcr Equal to 55 mL/min or Greater If a dose of Cefazolin for Injection and Dextrose Injection is required that does not equal 1 gram, 2 grams, or 3 grams this product is not recommended for use and an alternative formulation of cefazolin should be considered.. Site and Type of Infection Dose Frequency Moderate to severe infections 500 mg to 1 gram every 6 to 8 hours Mild infections caused by susceptible gram-positive cocci 250 mg to 500 mg every 8 hours Acute, uncomplicated urinary tract infections 1 gram every 12 hours Pneumococcal pneumonia 500 mg every 12 hours Severe, life-threatening infections (e.g., endocarditis, septicemia) In rare instances, doses of up to 12 grams of cefazolin per day have been used. 1 gram to 1.5 grams every 6 hours Dosage for the Treatment of Infections in Pediatric Patients with CLcr Equal to 70 mL/min or Greater The recommended pediatric dosages for the treatment of infections [see Indications and Usage (1.1 to 1.8)] are outlined in Table 2 below.
Administer Cefazolin for Injection and Dextrose Injection intravenously over approximately 30 minutes. If a dose of Cefazolin for Injection and Dextrose Injection is required that does not equal 1 gram, 2 grams or 3 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered [see Use in Specific Populations (8.4)].
Table 2: Recommended Dosage in Pediatric Patients with CLcr 70 mL/min or greater for Treatment of Infections [see Indications and Usage (1.1 to 1.8)] Type of Severity Recommended Total Daily Dosage Mild to moderate infections 25 mg/kg to 50 mg/kg, divided into 3 or 4 equal doses Severe infections May increase to 100 mg/kg, divided into 3 or 4 equal doses
2.3 Dosage for Perioperative Prophylaxis
2.3 Dosage for Perioperative Prophylaxis Dosage for Perioperative Prophylaxis in Adults with CLcr Equal to 55 mL/min or Greater To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended dosages are described in Table 3 below. Table 3: Recommended Dosage for Perioperative Prophylaxis in Adults with CLcr Equal to 55 mL/min or Greater Body weight (kg) Dose administered 1/2 hour to 1 hour prior to the start of surgery Additional dose during lengthy operative procedures (e.g., 2 hours or more) Dose for 24 hours postoperatively Less than 120 kg 1 gram to 2 grams 500 mg to 1 gram 500 mg to 1 gram every 6 hours to 8 hours Greater than or equal to 120 kg 3 grams If a dose of Cefazolin for Injection and Dextrose Injection is required that does not equal 1 gram, 2 grams, or 3 grams, this product is not recommended and an alternative formulation of cefazolin should be considered.
It is important that (i) the preoperative dose be given just prior (1/2 hour to 1 hour) to the start of surgery so that adequate antibacterial concentrations are present in the serum and tissues at the time of initial surgical incision; and (ii) cefazolin be administered, if necessary, at appropriate intervals during surgery to provide sufficient concentrations of the antibacterial drug at the anticipated moments of greatest exposure to infective organisms. The perioperative prophylactic administration of cefazolin should usually be discontinued within a 24-hour period after the surgical procedure.
In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of cefazolin may be continued for 3 days to 5 days following the completion of surgery. Dosage for Perioperative Prophyla xis in Pediatric Patients Aged 10 to 17 Years Old with CLcr 70 mL/min or Greater To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are described in Table 4 below.
Table 4: Recommended Dosage for Perioperative Prophylaxis in Pediatric Patients with CLcr 70 mL/min or greater Aged 10 to 17 years Old If a dose of Cefazolin for Injection and Dextrose Injection is required that does not equal 1 gram or 2 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered. Body weight (kg) Dose administered 1/2 to 1 hour prior to the start of surgery Additional dose during lengthy operative procedures (e.g., 2 hours or more) Dose for 24 hours postoperatively Less than 50 kg 1 gram 500 mg to 1 gram 500 mg to 1 gram every 6 hours to 8 hours Greater than or equal to 50 kg and less than 120 kg 2 grams It is important that (i) the preoperative dose be given just prior (1/2 hour to 1 hour) to the start of surgery so that adequate antibacterial concentrations are present in the serum and tissues at the time of initial surgical incision; and (ii) cefazolin be administered, if necessary, at appropriate intervals during surgery to provide sufficient concentrations of the antibacterial drug at the anticipated moments of greatest exposure to infective organisms.
The administration of Cefazolin for Injection and Dextrose Injection for perioperative prophylaxis should usually be discontinued within a 24-hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating the administration of Cefazolin for Injection and Dextrose Injection for perioperative prophylaxis may be continued for 3 days to 5 days following the completion of surgery.
2.4 Dosage Recommendations in Adult and Pediatric Patients with Renal Impairment
2.4 Dosage Recommendations in Adult and Pediatric Patients with Renal Impairment Dosage Recommendations in Adult Patients with CLcr less than 55 mL/min The dosage recommendation for Cefazolin for Injection and Dextrose Injection in adult patients with renal impairment (CLcr less than 55 mL/min) is outlined in Table 5 below. Table 5: Dosage Recommendation for Adult Patients with CLcr less than 55 mL/min Creatinine Clearance Dose Frequency 35 to 54 mL/min Recommended dose every 8 hours or longer 11 to 34 mL/min Half of recommended dose If the recommended dose in adult patients with creatinine clearance equal to 35 mL/min or greater is 1 gram, then this product is not recommended for use in patients with creatinine clearance less than 35 mL/min and an alternative formulation of cefazolin should be considered. every 12 hours 10 mL/min or less Half of recommended dose every 18 to 24 hours Dosage Recommendations in Pediatric Patients with CLcr less than 70 mL/min The dosage recommendation for Cefazolin for Injection and Dextrose Injection in pediatric patients with renal impairment (CLcr less than 70 mL/min) is outlined in Table 6 below.
Table 6: Recommended Dosage in Pediatric Patients with CLcr less than 70 mL/min Creatinine Clearance Recommended Dosage 40 to 70 mL/min 60% of the normal daily dose given in equally divided doses every 12 hours 20 to 40 mL/min 25% of the normal daily dose given in equally divided doses every 12 hours 5 to 20 mL/min 10% of the normal daily dose every 24 hours *If a dose of Cefazolin for Injection and Dextrose Injection is required that does not equal 1 gram, 2 grams, or 3 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered.
2.5 Preparation for Use of Cefazolin for Injection and Dextrose
2.5 Preparation for Use of Cefazolin for Injection and Dextrose Injection in DUPLEX ® Container This reconstituted solution of Cefazolin for Injection and Dextrose Injection is for intravenous use only. Do not use plastic containers in series connections. Such use would result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete.
If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Use only if solution is clear and container and seals are intact.
DUPLEX ® Container Storage To avoid inadvertent activation, the DUPLEX ® Container should remain in the folded position until activation is intended. Patient Labeling and Drug Powder/Diluent Inspection Apply patient-specific label on foil side of container. Use care to avoid activation. Do not cover any portion of foil strip with patient label.
Unlatch side tab and unfold DUPLEX ® Container (see Diagram 1). Visually inspect diluent chamber for particulate matter. Use only if container and seals are intact. To inspect the drug powder for foreign matter or discoloration, peel foil strip from drug chamber (see Diagram 2). Protect from light after removal of foil strip.
Note: If foil strip is removed, the container should be re-folded and the side tab latched until ready to activate. The product must then be used within 7 days, but not beyond the labeled expiration date. Reconstitution (Activation) Do not use directly after storage by refrigeration, allow the product to equilibrate to room temperature before patient use.
Unfold the DUPLEX ® Container and point the set port in a downward direction. Starting at the hanger tab end, fold the DUPLEX ® Container just below the diluent meniscus trapping all air above the fold. To activate, squeeze the folded diluent chamber until the seal between the diluent and powder opens, releasing diluent into the drug powder chamber (see Diagram 3).
Agitate the liquid-powder mixture until the drug powder is completely dissolved. Note: Following reconstitution (activation), product must be used within 24 hours if stored at room temperature or within 7 days if stored under refrigeration. Administration Visually inspect the reconstituted solution for particulate matter.
Point the set port in a downwards direction. Starting at the hanger tab end, fold the DUPLEX ® Container just below the solution meniscus trapping all air above the fold. Squeeze the folded DUPLEX ® Container until the seal between reconstituted drug solution and set port opens, releasing liquid to set port (see Diagram 4).
Prior to attaching the IV set, check for minute leaks by squeezing container firmly. If leaks are found, discard container and solution as sterility may be compromised. Using aseptic technique, peel foil cover from the set port and attach sterile administration set (see Diagram 5). Refer to directions for use accompanying the administration set.
Important Administration Instructions Do not use in series connections. Do not introduce additives into the DUPLEX ® Container. Administer Cefazolin for Injection and Dextrose Injection intravenously over approximately 30 minutes. Diagram 1 Diagram 2 Diagram 3 Diagram 4 Diagram 5
Dosing: Altered kidney function
Cefazolin is excreted unchanged in the urine (70% to 80% in 24 hours). The US label keeps the usual dose down to a creatinine clearance (CrCl) of 55 mL/min, then lengthens the interval or halves the dose as CrCl falls; seizures can occur when doses are not reduced. The label gives no dialysis dosing; a literature thrice-weekly post-hemodialysis regimen and ISPD 2022 intraperitoneal doses for peritonitis are shown as non-label options.
Kidney function measure: Label uses CrCl (mL/min; Cockcroft–Gault). Adults: adjust below 55. Children: adjust below 70.
Show full dosing details
- CrCl ≥60 mL/min
- CrCl ≥55: usual dose (label).
- CrCl 30–59 mL/min
- CrCl 55–59: usual dose. CrCl 35–54: usual dose every 8 hours or longer. CrCl 30–34: half the usual dose every 12 hours (label Table 5: CrCl 35–54, usual dose every 8 hours or longer; 11–34, half the usual dose every 12 hours; 10 or less, half the usual dose every 18 to 24 hours).
- CrCl 15–29 mL/min
- CrCl 11–34: half the usual dose every 12 hours (label Table 5: CrCl 35–54, usual dose every 8 hours or longer; 11–34, half the usual dose every 12 hours; 10 or less, half the usual dose every 18 to 24 hours).
- CrCl <15 mL/min (not on dialysis)
- CrCl 11–14: half the usual dose every 12 hours. CrCl 10 or less: half the usual dose every 18 to 24 hours (label Table 5: CrCl 35–54, usual dose every 8 hours or longer; 11–34, half the usual dose every 12 hours; 10 or less, half the usual dose every 18 to 24 hours).
- Hemodialysis (intermittent)
- Label: no hemodialysis dosing. Literature option (not label): thrice-weekly after each session, 2 g, 2 g and 2 g, or 2 g, 2 g and 3 g (the 3 g dose after the session before the 72-hour gap may be considered for MSSA bacteremia) (Tsai 2025). These regimens are not weight-adjusted and come mostly from small pharmacokinetic studies; confirm the actual last and next session before each dose. See the site guide Antibiotic Stewardship in Hemodialysis (/guides/antibiotic-stewardship-dialysis.html).
- Peritoneal dialysis
- Label: no peritoneal dialysis dosing. For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 15 mg/kg daily (long dwell) or 20 mg/kg daily (short dwell); continuous loading dose 500 mg/L, then 125 mg/L in each exchange. Continuous cephalosporin doses may need about 25% more in patients with significant residual kidney function (ISPD 2022).
- CRRT
- Not in label; the cited CRRT review (Li 2020) gives no regimen for this drug. Specialist input.
- Dialyzable? Not stated in the US label.
- Monitoring CrCl for dose; seizures with excess doses in kidney impairment (label 5.2); prothrombin time in patients at risk of low prothrombin activity (label).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- CrCl ≥70: usual dose. CrCl 60–69: 60% of the normal daily dose, divided every 12 hours (label Table 6).
- eGFR 30–59
- CrCl 40–70: 60% of the normal daily dose divided every 12 hours; CrCl 20–40: 25% of the normal daily dose divided every 12 hours (label Table 6).
- eGFR 15–29
- CrCl 20–40: 25% of the normal daily dose divided every 12 hours; CrCl 5–20: 10% of the normal daily dose every 24 hours (label Table 6).
- eGFR <15 (not on dialysis)
- CrCl 5–20: 10% of the normal daily dose every 24 hours (label Table 6). Below 5: not stated; specialist input.
- Hemodialysis (intermittent)
- No pediatric dialysis data in label. Specialist input.
- Peritoneal dialysis
- No pediatric dialysis dosing in label. Specialist input.
- CRRT
- No pediatric CRRT data in the cited sources. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
2.4 Dosage Recommendations in Adult and Pediatric Patients with Renal Impairment Dosage Recommendations in Adult Patients with CLcr less than 55 mL/min The dosage recommendation for Cefazolin for Injection and Dextrose Injection in adult patients with renal impairment (CLcr less than 55 mL/min) is outlined in Table 5 below. Table 5: Dosage Recommendation for Adult Patients with CLcr less than 55 mL/min Creatinine Clearance Dose Frequency 35 to 54 mL/min Recommended dose every 8 hours or longer 11 to 34 mL/min Half of recommended dose If the recommended dose in adult patients with creatinine clearance equal to 35 mL/min or greater is 1 gram, then this product is not recommended for use in patients with creatinine clearance less than 35 mL/min and an alternative formulation of cefazolin should be considered. every 12 hours 10 mL/min or less Half of recommended dose every 18 to 24 hours Dosage Recommendations in Pediatric Patients with CLcr less than 70 mL/min The dosage recommendation for Cefazolin for Injection and Dextrose Injection in pediatric patients with renal impairment (CLcr less than 70 mL/min) is outlined in Table 6 below.
Table 6: Recommended Dosage in Pediatric Patients with CLcr less than 70 mL/min Creatinine Clearance Recommended Dosage 40 to 70 mL/min 60% of the normal daily dose given in equally divided doses every 12 hours 20 to 40 mL/min 25% of the normal daily dose given in equally divided doses every 12 hours 5 to 20 mL/min 10% of the normal daily dose every 24 hours *If a dose of Cefazolin for Injection and Dextrose Injection is required that does not equal 1 gram, 2 grams, or 3 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered.
8.6 Patients with Renal Impairment When Cefazolin for Injection and Dextrose Injection is administered to adult and pediatric patients with low urinary output because of impaired renal function (creatinine clearance less than 55 mL/min and 70 mL/min for adults and pediatric patients, respectively), lower daily dosage is required [see Dosage and Administration (2.4) and Warnings and Precautions (5.2)].
Dosing: Pediatric
- Approved ages
- Children for treatment indications when the needed dose matches an available formulation (DUPLEX label); perioperative prophylaxis 10 to 17 years (DUPLEX label). The alternate WG Critical Care 2 g/3 g vial label: pediatric prophylaxis not established.
- Usual dose
- 25 to 50 mg/kg/day in 3 or 4 divided doses; severe infections up to 100 mg/kg/day (label, CrCl ≥70).
- Maximum dose
- 100 mg/kg/day, not above the adult dose (label).
Label pediatric table uses CrCl (mL/min); the site band labels are eGFR.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use Cefazolin for Injection and Dextrose Injection is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and skin structure infections, biliary tract infections, bone and joint infections, genital infections, septicemia, and endocarditis in pediatric patients for whom appropriate dosing with this formulation can be achieved, and for perioperative prophylaxis in pediatric patients aged 10 to 17 years old [see Indications and Usage (1.1 to 1.9)]. Safety and effectiveness of Cefazolin for Injection and Dextrose Injection in premature infants and neonates have not been established and is not recommended for use in this age group of pediatric patients.
Dosing for cefazolin in pediatric patients younger than one month old has not been established. Because of the limitations of the available strengths and administration requirements (i.e., administration of fractional doses is not recommended) of Cefazolin for Injection and Dextrose Injection, and to avoid unintentional overdose, this product is not recommended for use if a dose of Cefazolin for Injection and Dextrose Injection that does not equal 1 gram or 2 grams is required and an alternative formulation of cefazolin should be considered [see Dosage and Administration (2.2, 2.3, 2.4 and 2.5)].
The safety and effectiveness of Cefazolin for Injection and Dextrose Injection for perioperative prophylaxis have been established in pediatric patients aged 10 to 17 years old. Use of Cefazolin for Injection and Dextrose Injection in these age groups is supported by evidence from adults with additional safety and pharmacokinetic data in pediatric patients aged 10 to 17 years old.
Safety and pharmacokinetics were evaluated in two multicenter, non-comparative studies (Study 1 and Study 2). These studies were conducted to assess the safety and pharmacokinetics of a single 30-minute infusion of either 1 gram or 2 grams (based on weight) of Cefazolin for Injection and Dextrose Injection for perioperative prophylaxis in pediatric patients.
Study 1 evaluated the safety and pharmacokinetics of 1 gram of Cefazolin for Injection and Dextrose Injection in pediatric patients aged 10 to 17 years old scheduled for surgery with a weight of at least 25 kg but less than 60 kg and, 2 grams in pediatric patients with a weight of at least 60 kg. Study 2 evaluated 1 gram of Cefazolin for Injection and Dextrose Injection in pediatric patients aged 10 to 12 years old scheduled for surgery with a weight of at least 25 kg but less than 50 kg and, 2 grams in pediatric patients with a weight of at least 50 kg to less than 85 kg [see Dosage and Administration (2.3), Adverse Reactions (6.1) and Clinical Pharmacology (12.3)].
The safety and effectiveness of Cefazolin for Injection and Dextrose Injection for perioperative prophylaxis have not been established in pediatric patients younger than 10 years old.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the 920 subjects who received cefazolin in clinical studies, 313 (34%) were 65 years and over, while 138 (15%) were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2. 4) and Warnings and Precautions (5.2)].
Administration
2.1 Important Administration Instructions If a dose of Cefazolin for Injection and Dextrose Injection is required that does not equal 1 gram, 2 grams, or 3 grams, this product is not recommended for use and an alternative formulation of cefazolin should be considered. Administer Cefazolin for Injection and Dextrose Injection intravenously over approximately 30 minutes.
2.5 Preparation for Use of Cefazolin for Injection and Dextrose Injection in DUPLEX ® Container This reconstituted solution of Cefazolin for Injection and Dextrose Injection is for intravenous use only. Do not use plastic containers in series connections. Such use would result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete. If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Use only if solution is clear and container and seals are intact. DUPLEX ® Container Storage To avoid inadvertent activation, the DUPLEX ® Container should remain in the folded position until activation is intended. Patient Labeling and Drug Powder/Diluent Inspection Apply patient-specific label on foil side of container. Use care to avoid activation. Do not cover any portion of foil strip with patient label. Unlatch side tab and unfold DUPLEX ® Container (see Diagram 1 ). Visually inspect diluent chamber for particulate matter. Use only if container and seals are intact. To inspect the drug powder for foreign matter or discoloration, peel foil strip from drug chamber (see Diagram 2 ). Protect from light after removal of foil strip. Note: If foil strip is removed, the container should be re-folded and the side tab latched until ready to activate. The product must then be used within 7 days, but not beyond the labeled expiration date. Reconstitution (Activation) Do not use directly after storage by refrigeration, allow the product to equilibrate to room temperature before patient use. Unfold the DUPLEX ® Container and point the set port in a downward direction. Starting at the hanger tab end, fold the DUPLEX ® Container just below the diluent meniscus trapping all air above the fold. To activate, squeeze the folded diluent chamber until the seal between the diluent and powder opens, releasing diluent into the drug powder chamber (see Diagram 3 ). Agitate the liquid-powder mixture until the drug powder is completely dissolved. Note: Following reconstitution (activation), product must be used within 24 hours if stored at room temperature or within 7 days if stored under refrigeration. Administration Visually inspect the reconstituted solution for particulate matter. Point the set port in a downwards direction. Starting at the hanger tab end, fold the DUPLEX ® Container just below the solution meniscus trapping all air above the fold. Squeeze the folded DUPLEX ® Container until the seal between reconstituted drug solution and set port opens, releasing liquid to set port (see Diagram 4 ). Prior to attaching the IV set, check for minute leaks by squeezing container firmly. If leaks are found, discard container and solution as sterility may be compromised. Using aseptic technique, peel foil cover from the set port and attach sterile administration set (see Diagram 5 ). Refer to directions for use accompanying the administration set. Important Administration Instructions Do not use in series connections. Do not introduce additives into the DUPLEX ® Container. Administer Cefazolin for Injection and Dextrose Injection intravenously over approximately 30 minutes. Diagram 1 Diagram 2 Diagram 3 Diagram 4 Diagram 5
US FDA labelDosage forms
Philippines
- Powder for injection: 1 g, 500 mg
- Powder for solution for injection: 1 g
- Dry powder for injection: 1 g
- Powder for solution: 1 g
Registered products in the Philippines
48 products registered with the Food and Drug Administration (FDA) Philippines list Cefazolin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products48
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AcefinCefazolin (as sodium) | 1 g Powder for Injection (I.M./I.V.)Individually boxed 10 mL Borosilicate Glass Vial with Blue Flip-off Seal Box of 10's | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | AMB HK Enterprises Inc. | DRP-3571 | Dec 3, 2028 | |
AmezolinCefazolin (as Sodium) | 1 g Powder for Injection (IM/IV)10 mL USP Type I Clear and Colorless Glass Vial with Blue Flip- off Seal + 5 mL Ampoule Sterile Water for Injection (as diluent) (Box of 1's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Amedesons Drug HouseImporter: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9970-02 | Aug 19, 2029 | |
BacefazCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)10 mL-capacity USP Type I Vial with rubber stopper and aluminum flip off seal + 1 ampoule x 10 mL Water for Injection (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | GPC Geo Pharma Corporation. | DRP-15200 | May 24, 2029 | |
BaczinCefazolin (as Sodium) | 1g Powder For Injection (IM/IV)Type III Clear Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Aluminum Plastic Cap x 10 mL (Box of 10's) | Rx | NCPC Hebei Huamin Pharmaceutical Company LimitedChina | GPC Geo Pharma CorporationTrader: Kwan Star Co., Ltd. | DRP-11876 | May 18, 2027 | |
CefacareCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)7 mL Type II Clear Glass Vial with Halogenated Butyl Rubber Stopper Coated with Polytetrafluoroethylene and Crimped with Alu-plastic Flip-off Cap (Box of 1’s) | Rx | Zhuhai United Laboratories (Zhongsan) Co., Ltd.China | Aglobal Care, Inc. | DRP-10263 | Feb 6, 2027 | |
CefarexCefazolin (as sodium) | 1 g Powder for Injection (IV/IM)10 mL Clear Colorless USP Type I Glass Vial + 5 mL Sterile Water for Injection (Diluent) in Ampoule (Box of 10's) | Rx | JIANGXI XIERKANGTAI PHARMACEUTICAL CO., LTD.China | AAREX PHARMA DISTRIBUTORTrader: Advacare International Limited | DR-XY46036 | Sep 18, 2027 | |
CefavexCefazolin (as Sodium) | 1 g Powder for Injection (I.M./I.V.)USP Type III clear, colorless glass vial with aluminum plastic cap (Box of 10's with individual box per vial) | Rx | North China Pharmaceutical Co., Ltd.China | Sannovex Pharmaceutical Distributor | DRP-3718 | Apr 17, 2027 | |
CefavexCefazolin (As Sodium) | 1 g Powder for Injection (IM/IV)USP Type III Clear Colorless Glass Vial with Aluminum Plastic Cap and Halogenated Butyl Rubber Stopper (Box of 10's) | Rx | NPC Hebei Huamin Pharmaceutical Co., Ltd.China | Sannovex Pharmaceutical Distributor | DRP-12399 | Aug 2, 2027 | |
CefazobasCefazolin (as Sodium) | 1 g Powder for Injection (IM/IV)10 mL USP Type I Clear and Colorless Glass Vial with Blue Flip-off Seal + 5 mL Ampoule Sterile Water for Injection (as diluent) (Box of 1's) | Rx | FRIENDS PHARMA (PVT.) LTD.Pakistan | RAQUEL-ABBAS PHARMACEUTICALS & GENERAL MERCHANDISE | DRP-9970 | Aug 19, 2029 | |
CEFAZODENCefazolin (as sodium ) | 1 g Powder for Injection (IM/IV)Individually Boxed USP Type I Clear and Colorless Glass Vial with Blue Flip-off Seal (Box of 10's ) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., LtdChina | Cyden Medicale Trading Inc.Importer: AMB HK ENTERPRISES INC. | DRP-3572-02 | Apr 4, 2029 | |
CefazogetCefazolin (as sodium) | 1 g Powder for Solution for Injection (IM/IV/IV Infusion)Plain Glass Vial x 10 mL (Box of 1's) | Rx | Swiss Parenterals Ltd.India | 2MG Incorporated | DRP-15508 | Jul 30, 2029 | |
Cefazomax-1Cefazolin (as sodium) | 1g Powder for Injection (IM/IV)10mL mould vial, flip-off cap, butyl rubber stopper, adhesive label. | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dreamax Incorporated | DRP-14501 | Sep 14, 2028 | |
Cefazosaph-1Cefazolin (As Sodium) | 1g Powder for Injection (IM/IV)Type I Clear Glass Flint Vial with Gray Bromobutyl Rubber Stopper and Gray Aluminum Flip-Off Seal Cap x l's (Box of l's and 10's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11174 | Feb 10, 2027 | |
CefazovinCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)Type III Clear Colorless Glass Vial with Grey Butyl Rubber Stopper and Sealed with Blue Flip-off Aluminum Cap (Box of 1’s and 10’s) | Rx | NCPC Hebei Huamin Pharmaceutical Co. Ltd.,China | Vintel Med EnterprisesImporter: Aglobal Care, Inc. | DRP-8075-05 | May 18, 2028 | |
CefazovitCefazolin Sodium | 1 g Powder for Injection (I.M. / I.V.)Clear, colorless, Type I glass vial with rubber stopper and blue flip-off seal, 1 g in individual box (Box of 10) | Rx | Vitalis S.A.C.I.Colombia | Pan-Ject Pharmaceuticals Corp.Trader: Vitalis S.A.C.I. | DR-XY35065 | Oct 24, 2028 | |
CizolinCefazolin (as sodium) | 1 g Powder for Injection (I.M./I.V.)Individually boxed USP Type I Clear Colorless Glass Vial with Blue Flip-Off Seal Box of 10's | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | ICare Pharmaceutical Philippines IncorporatedImporter: AMB HK ENTERPRISES INC. | DRP-3572 | Apr 4, 2029 | |
EozolineCefazolin (as sodium) | 1g Powder for Solution (IM/IV)Glass vial with halogenated butyl rubber stopper and aluminum cap x 7 ml (Box of l's and Box of 10's) | Rx | NCPC Hebei Huamin Pharmaceutical Company LimitedChina | Eon Pharmatek Inc. | DR-XY47853 | Mar 30, 2027 | |
FazefCefazolin (as sodium) | 1 g Powder for InjectionUSP Type III clear and colorless glass vial (in individual box) with light blue flip-off seal | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | The Cathay Drug Co., Inc.Importer: Baxter Healthcare Philippines Inc.Trader: Baxter Pharmaceuticals India Private Limited | DRP-6590-01 | Jul 30, 2030 | |
FazefCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)Type III Clear Colorless Glass Vial with Grey Butyl Rubber Stopper and Sealed with Blue Flip-off Aluminum Cap (Box of 1’s) | Rx | NCPC Hebei Huamin Pharmaceutical Co., Ltd.China | The Cathay Drug Co., Inc.Importer: Aglobal Care, Inc. | DRP-8075-02 | May 18, 2028 | |
FazlinCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)Type III Clear Colorless Glass Vial with Grey Butyl Rubber Stopper and Sealed with Blue Flip-off Aluminum Cap (Box of 1’s and 10’s) | Rx | NCPC Hebei Huamin Pharmaceutical Co., Ltd.China | Aglobal Care, Inc. | DRP-8075 | May 18, 2028 | |
FazolinCefazolin (as Sodium) | 1 g Powder for Injection (I.M./I.V.)USP Type III Clear Glass Vial with Rubber Stopper and Blue Flip Off Seal (Box of 10's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Health Saver Pharma Inc. | DRP-2029 | Mar 14, 2027 | |
FazonilCefazolin (as Sodium) | 1 g Powder for Injection (I.M./I.V.)USP Type I Vial with Rubber Stopper Sealed with purplish red flip-off Aluminum Seal Box of 10's | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | — | DR-XY36829 | Jan 12, 2030 | |
FazorixxCefazolin (as Sodium) | 1 g Powder for Injection (I.M./I.V.)Individually boxed 10 mL Borosilicate Glass Vial with Blue Flip-off seal x 10mL Diluent Box of 10's | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Bio Erixx Pharma DistributionImporter: AMB HK Enteprises Inc. | DRP-3571-01 | Dec 3, 2028 | |
FazosaphCefazolin (As Sodium) | 1g Powder For Injection (IM/IV)10 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and royal blue aluminum flip-off seal (Box of 1's) | Rx | Bueno Salud Care (India) Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13477 | Feb 27, 2028 | |
FazterraCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)10 mL capacity USP Type III glass vial with rubber stopper and flip-off seal (Box of 1's) | Rx | Finebiotics Pharma Ltd.India | Santerra TradingImporter: Medinova Pharmaceutical Inc. | DRP-15460-01 | Jul 11, 2029 | |
GozolinCefazolin (as sodium) | 1 g Powder for Injection (I.M/I.V)Individually boxed USP Type I Clear Colorless Glass Vial with Blue Flip-Off Seal (Box of 10’s) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Applied Pharmaceutical Distribution IncImporter: AMB HK Enterprises Inc. | DRP-3572-03 | Apr 4, 2029 | |
HazolinCefazolin (as Sodium) | 1g Powder for Injection (I.M./I.V.)USP Type I clear glass vial with rubber stopper and blue flip-off seal (Box of 10's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm FactoryChina | Endure Medical, Inc. | DRP-1378 | Feb 7, 2028 | |
HazolinCefazolin (as Sodium) | 500 mg Powder for Injection (IM/IV)USP Type I clear glass vial with rubber stopper and blue flip-off seal (Box of 10's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Endure Medical, Inc. | DRP-1654 | Feb 7, 2028 | |
LeklinCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)USP Type I Clear and Colorless Glass Vial with Rubber Stopper and Blue Flip-off Seal (Box of 1’s) | Rx | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals and Pharmaceuticals Limited)India | JBCPL Philippines Inc. | DRP-858 | Apr 7, 2028 | |
LocefCefazolin (as sodium) | 1 g Powder for InjectionUSP Type III clear and colorless glass vial (in individual box) with light blue flip-off seal | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | Baxter Healthcare Philippines Inc.Trader: Baxter Pharmaceuticals India Private Limited | DRP-6590 | Jul 30, 2030 | |
LupexCefazolin Sodium | 1 g Powder for Injection (IM/IV)Glass Vial with Green Flip-off Seal x 1g (Box of 10's) | Rx | Yung Shin Pharm. Ind. Co., Ltd. (Taichung Youth Factory III)Taiwan | Yung Shin (Philippines), Inc. | DR-XY14753 | Jan 31, 2030 | |
MaxolinCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)10-mL capacity clear borosilicate glass vial with halogenated butyl rubber stopper and aluminum plastic cap (Box of 10’S) | Rx | NCPC Hebei Huamin Pharmaceutical Company LimitedChina | AMB HK Enterprises Inc. | DRP-9143 | Nov 3, 2030 | |
NoneCefazolin (as Sodium) | 1 g Powder For Injection (IM/IV)Borosilicate Vial With Aluminum Seal And Red Flip-Off Plastic Cap (Box Of 10's) | Rx | Sinopharm Zhijun (Shenzhen) Pharmaceutical Co., Ltd.China | Importer: Dynasty Pharmaceuticals | DRP-8293 | Jun 22, 2027 | |
NovazolinCefazolin (As Sodium) | 1 g Powder for Injection (IM/IV)Type I Clear Colorless Glass Vial Sealed with 20 mm Grey Butyl Rubber Stopper and 20 mm Flip-off Seal x 15 mL (Box of 1’s) | Rx | Swiss Parenterals Ltd.India | Medinova Pharmaceutical Inc. | DRP-11889 | May 18, 2027 | |
NovazolinCefazolin (as Sodium) | 500mg Powder for Injection (IM/IV)15 mL-capacity USP Type I clear glass vial with gray bromobutyl rubber stopper and aluminum dark brown. flip-off cap (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Medinova Pharmaceutical Inc. | DRP-14140 | Jun 30, 2028 | |
PharcinCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)Type I Glass Vial + 10 mL Diluent Type I Glass Ampoule per box | Rx | Utopian Co., Ltd.Thailand | GPC Geo Pharma Corporation | DRP-2441 | Mar 5, 2031 | |
PhizolinCefazolin (as Sodium) | 1 g Powder for Injection (IM/IV)Individually boxed USP Type I Clear Colorless Glass Vial with Blue Flip-Off Seal (Box of 10’s) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-3572-01 | Apr 4, 2029 | |
RaxivitCefazolin (as sodium) | 1 g Powder for Injection10 mL capacity USP Type III glass vial with rubber stopper and flip-off seal (Box of 1's) | Rx | Finebiotics Pharma Ltd.India | RCT Med Pharma CorporationImporter: Medinova Pharmaceutical Inc. | DRP-15460-02 | Jul 11, 2029 | |
RylinCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)Type III Clear Colorless Glass Vial with Grey Butyl Rubber Stopper and Sealed with Blue-off Aluminum Cap (Box of 1's and 10's) | Rx | NCPC Hebei Huamin Pharmaceutical Co., Ltd.China | Tamiga Pharmaceuticals SupplyImporter: Aglobal Care, Inc. | DRP-8075-03 | May 18, 2028 | |
SamarialCefazolin (as sodium) | 1 g Powder for Injection (I.M./I.V.)USP Type I clear and colorless glass vial (Box of 10 vials) | Rx | Samjin Pharmaceutical Co., Ltd.Republic of Korea | Unimex, Inc. | DR-XY30957 | Aug 5, 2031 | |
SanazolinCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)7 mL-capacity clear glass vial with rubber stopper and aluminum cap (Box of 10's) | Rx | NCPC Hebei Huamin Pharmaceutical Company LimitedChina | Golden Life Pharmaceutical Product Distribution.Trader: Salubris Pharmaceuticals Limited | DRP-16410 | Mar 10, 2030 | |
StancefCefazolin | 1 g Powder for Injection (IM/IV)10 mL Type I Clear Vial with Yellow Flip-off Aluminum Cap and Alucap Gold (Box of 1's and 10's with plastic tray) | Rx | PT. Darya-Varia Laboratoria TBKlndonesia | UNILAB, Inc. | DR-XY39640 | Jun 16, 2031 | |
StancefCefazolin | 500 mg Powder for Injection (IM/IV)10 mL Type I Clear Vial (Box of 1's) | Rx | PT. Darya-Varia Laboratoria TBKlndonesia | UNILAB, Inc. | DR-XY39651 | Jul 1, 2036 | |
SuporinCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)10 ml Colorless Glass Vial Closed with Grey Butyl Rubber Stopper and Sealed with Parrot Green Colored Seal Caps, Embossed Umedica Logo | Rx | Inject Care Parenterals Pvt. Ltd.India | Suhitas Pharmaceuticals, Inc.Trader: Umedica Laboratories Pvt. Ltd. | DRP-1780 | Feb 1, 2031 | |
ZefamaxCefazolin (as sodium) | 1 g Powder for Injection (IM/IV)Type Clear Colorless Glass Vial With Grey Butyl Rubber Stopper And Sealed With Blue Flip-Off Aluminum Cap (Box of 1's) | Rx | NCPC Hebei Huamin Pharmaceutical Co., Ltd.China | Zyre Pharmaceuticals CorporationImporter: Aglobal Care, Inc. | DRP-8075-04 | May 18, 2028 | |
Zolin-IVCefazolin (as sodium) | 1 g Powder for Solution for Injection (IM/IV)Tubular Vial with Grey Halogenated Butyl Rubber Stopper and Al-Plastics Combination Cap x 10 mL (Box of 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Dreamax Incorporated | DRP-15477 | Jul 12, 2029 | |
Zolinova IVCefazolin (as sodium) | 1g Dry Powder For Injection10 ml clear glass vial USP Type III, with butyl rubber stopper, flip-off seal; Box of 1's | Rx | Finebiotics Pharma Ltd.India | Medinova Pharmaceutical Inc. | DRP-15460 | Jul 11, 2029 | |
(no brand name)Cefazolin (As Sodium) | 1g Powder For Injection (IM/IV)Type III glass vial with grey butyl rubber stopper, aluminum flip-off seal, and plastic cap (Box of 10's) | Rx | NCPC Hebei Huamin Pharmaceutical Company LimitedChina | Kwanstar Pharma Distributor | DRP-11850 | May 10, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Dual-chamber, single-dose packaged combination of Cefazolin Sodium USP (lyophilized) and sterile iso-osmotic diluent in the DUPLEX ® sterile container consisting of: 1 gram Cefazolin for Injection USP and 50 mL 4% Dextrose Injection USP 2 grams Cefazolin for Injection USP and 50 mL 3% Dextrose Injection USP 3 grams Cefazolin for Injection USP and 50 mL 2% Dextrose Injection USP Dual-Chamber in single-dose Duplex ® Container: 1 gram Cefazolin for Injection USP and 50 mL 4% Dextrose Injection USP (3) 2 grams Cefazolin for Injection USP and 50 mL 3% Dextrose Injection USP (3) 3 grams Cefazolin for Injection USP and 50 mL 2% Dextrose Injection USP (3)
Warnings/Precautions
- Hypersensitivity reactions: Cross-hypersensitivity may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction occurs, discontinue the drug. (5.1)
- Clostridioides difficile -associated Diarrhea (CDAD): May range from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. (5.3)
- Prothrombin Activity: May be associated with a fall in prothrombin activity. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5)
5.1 Hypersensitivity Reactions to Cefazolin, Cephalosporins, Penicillins, or Other…
5.1 Hypersensitivity Reactions to Cefazolin, Cephalosporins, Penicillins, or Other Beta-lactams Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before therapy with Cefazolin for Injection and Dextrose Injection is instituted, careful inquiry should be made to determine whether the patient has had previous immediate hypersensitivity reactions to cefazolin, cephalosporins, penicillins, or carbapenems.
Exercise caution if this product is to be given to penicillin-sensitive patients because cross-hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to Cefazolin for Injection and Dextrose Injection occurs, discontinue the drug.
5.2 Seizures in Patients with Renal Impairment
5.2 Seizures in Patients with Renal Impairment Seizures may occur with the administration of Cefazolin for Injection and Dextrose Injection, particularly in patients with renal impairment when the dosage is not reduced appropriately. Discontinue Cefazolin for Injection and Dextrose Injection if seizures occur or make appropriate dosage adjustments in patients with renal impairment [see Dosage and Administration (2.4)].
Anticonvulsant therapy should be continued in patients with known seizure disorders.
5.3 Clostridioides difficile
5.3 Clostridioides difficile -associated Diarrhea Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefazolin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
5.4 Hypersensitivity to Dextrose-containing Products
5.4 Hypersensitivity to Dextrose-containing Products Hypersensitivity reactions, including anaphylaxis, have been reported with administration of dextrose-containing products. These reactions have been reported in patients receiving high concentrations of dextrose (i.e. 50% dextrose) 1. The reactions have also been reported when corn-derived dextrose solutions were administered to patients with or without a history of hypersensitivity to corn products. 2
5.5 Prothrombin Activity
5.5 Prothrombin Activity Cefazolin for Injection and Dextrose Injection may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy.
Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated.
5.6 Risk of Development of Drug-resistant Bacteria Prescribing
5.6 Risk of Development of Drug-resistant Bacteria Prescribing Cefazolin for Injection and Dextrose Injection in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. As with other antimicrobials, prolonged use of Cefazolin for Injection and Dextrose Injection may result in overgrowth of nonsusceptible microorganisms.
Repeated evaluation of the patient's condition is essential. Should superinfection occur during therapy, appropriate measures should be taken.
5.7 Drug/Laboratory Test Interactions Urinary Glucose
5.7 Drug/Laboratory Test Interactions Urinary Glucose The administration of cefazolin may result in a false-positive reaction with glucose in the urine when using glucose tests based on Benedict’s copper reduction reaction that determine the amount of reducing substances like glucose in the urine. It is recommended that glucose tests based on enzymatic glucose oxidase be used.
Coombs’ Test Positive direct Coombs' tests have been reported during treatment with cefazolin. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibacterial drugs before parturition, it should be recognized that a positive Coombs' test may be due to the drug.
5.8 Patients with Overt or Known Subclinical Diabetes Mellitus or Carbohydrate Intolerance
5.8 Patients with Overt or Known Subclinical Diabetes Mellitus or Carbohydrate Intolerance As with other dextrose-containing solutions, Cefazolin for Injection and Dextrose Injection should be prescribed with caution in patients with overt or known subclinical diabetes mellitus or carbohydrate intolerance for any reason.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Probenecid | Avoid | Blocks tubular secretion; higher and longer drug levels (label). | Coadministration not recommended. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
7 DRUG INTERACTIONS The renal excretion of cefazolin is inhibited by probenecid. Co-administration of probenecid with Cefazolin for Injection and Dextrose Injection is not recommended. Probenecid: The renal excretion of cefazolin is inhibited by probenecid. Co-administration of probenecid with cefazolin for injection is not recommended. (7)
Adverse reactions
Common
- Nausea, vomiting, diarrhea
- Allergic reactions (urticaria, skin rash)
Serious
- Anaphylaxis and serious hypersensitivity (cross-reactivity with penicillins up to 10%)
- Seizures in kidney impairment when doses are not reduced
- Clostridioides difficile-associated diarrhea
- Fall in prothrombin activity
The following serious adverse reactions to Cefazolin for Injection and Dextrose Injection are described below and elsewhere in the labeling: Hypersensitivity Reactions to Cefazolin, Cephalosporins, Penicillins, or Other Beta-lactams [see Warnings and Precautions (5.1)] Seizures in Patients with Renal Impairment [see Warnings and Precautions (5.2)] Clostridioides difficile -associated Diarrhea [see Warnings and Precautions (5.3)] Prothrombin Activity [see Warnings and Precautions (5.5)] Adult and Pediatric Patients: Most common adverse reactions: gastrointestinal (nausea, vomiting, diarrhea), and allergic reactions (anaphylaxis, urticaria, skin rash). (6) Pediatric Patients with Perioperative Prophylaxis: The most frequently reported adverse reactions (incidence ≥ 5%) were nausea, infusion site pain, and headache.
(6) To report SUSPECTED ADVERSE REACTIONS, contact B. Braun Medical Inc. at 1-800-854-6851 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The following adverse reactions were reported from clinical trials: Gastrointestinal: Diarrhea, oral candidiasis (oral thrush), mouth ulcers, vomiting, nausea, stomach cramps, epigastric pain, heartburn, flatus, anorexia and pseudomembranous colitis.
Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment [see Warnings and Precautions (5.3)]. Allergic: Anaphylaxis, eosinophilia, urticaria, itching, drug fever, skin rash, Stevens-Johnson syndrome. Hematologic: Neutropenia, leukopenia, thrombocytopenia, thrombocythemia. Hepatic: Transient rise in SGOT, SGPT, and alkaline phosphatase levels has been observed.
Reports of hepatitis have been received. Renal: Reports of increased BUN and creatinine levels, as well as renal failure, have been received. Local Reactions: Instances of phlebitis have been reported at site of injection. Some induration has occurred. Other Reactions: Pruritus (including genital, vulvar and anal pruritus, genital moniliasis, and vaginitis).
Dizziness, fainting, lightheadedness, confusion, weakness, tiredness, hypotension, somnolence and headache. Adverse Reactions in Pediatric Patients for Perioperative Prophylaxis Two studies (Study 1: NCT 3231228 and Study 2: NCT 01904357) were conducted to assess the safety and pharmacokinetics of a single 30-minute infusion of either 1 gram or 2 grams (based on weight) of Cefazolin for Injection and Dextrose Injection for perioperative prophylaxis in pediatric patients.
Study 1 was a multicenter, open-label, non-comparative, parallel group study to evaluate the safety and pharmacokinetics of a single 30-minute infusion of either 1 gram or 2 grams (based on weight) of Cefazolin for Injection and Dextrose Injection for perioperative prophylaxis in 61 pediatric patients 10 to 17 years of age. Thirty-three subjects with a weight of at least 25 kg but less than 60 kg received a single-dose of 1 gram of cefazolin and 28 subjects with a weight of at least 60 kg received a single-dose of 2 grams of cefazolin.
The mean age of the safety population was 14 years and ranged from 10 to 17 years. There were no adverse reactions leading to study discontinuation or deaths reported during the study. The most frequently reported adverse reactions were nausea (14.8%), infusion site pain (6.6%), and headache (4.9%). Study 2 was a multicenter, non-comparative study that evaluated the safety and pharmacokinetics of a single 30-minute infusion of either 1 gram or 2 grams (based on weight) of Cefazolin for Injection and Dextrose Injection for perioperative prophylaxis in 12 pediatric patients 10 to 12 years of age.
Subjects weighing at least 25 kg to less than 50 kg received a single-dose of 1 gram of Cefazolin for Injection and Dextrose Injection and subjects weighing at least 50 kg to less than 85 kg received a single-dose of 2 grams of Cefazolin for Injection and Dextrose Injection. The safety findings in Study 2 in pediatric patients aged 10 to 12 years old were similar to those observed in adult patients and the pediatric patients aged 10 to 17 years old in Study 1.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of cefazolin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Immune system disorders: Serum sickness-like reaction Renal and urinary disorders: Acute tubulointerstitial nephritis (ATIN) Skin and subcutaneous tissue disorders: Acute generalized exanthematous pustulosis (AGEP)
6.3 Cephalosporin-class Adverse Reactions
6.3 Cephalosporin-class Adverse Reactions In addition to the adverse reactions listed above that have been observed in patients treated with cefazolin, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterials: Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal impairment, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, a fall in prothrombin activity, hepatic impairment including cholestasis, and pancytopenia.
Monitoring parameters
- CrCl for dose; seizures with excess doses in kidney impairment (label 5.2); prothrombin time in patients at risk of low prothrombin activity (label). Kidney
- CrCl for dose
- Prothrombin time in patients at risk
- Signs of seizures in kidney impairment
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from published prospective cohort studies, case series and case reports over several decades with cephalosporin use, including cefazolin, in pregnant women have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Cefazolin crosses the placenta.
Animal reproduction studies with rats, mice and rabbits administered cefazolin during organogenesis at doses 1 to 3 times the maximum recommended human dose (MRHD) did not demonstrate adverse developmental outcomes. In rats subcutaneously administered cefazolin prior to delivery and throughout lactation, there were no adverse effects on offspring at a dose approximately 2 times the MRHD (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data Human Data While available studies cannot definitively establish the absence of risk, published data from case-control studies and case reports over several decades have not identified an association with cephalosporin use during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups.
Animal Data Reproduction studies have been performed in rats, mice and rabbits administered cefazolin during organogenesis at doses of 2000, 4000 and 240 mg/kg/day (approximately 1 to 3 times the maximum recommended human dose on a body surface area comparison). There was no evidence of any adverse effects on embryofetal development due to cefazolin.
In a peri-postnatal study in rats, cefazolin administered subcutaneously up to 1200 mg/kg/day (approximately 2 times the MRHD based on body surface area comparison) to pregnant dams prior to delivery and through lactation caused no adverse effects on offspring.
Mechanism of action
12.1 Mechanism of Action Cefazolin is an antibacterial drug [see Microbiology (12.4)].
US FDA labelPharmacokinetics
Key PK parameters
| Time to peak | About 185 mcg/mL after 1 g IV |
|---|---|
| Half-life | About 1.8 hours (IV) |
| Volume of distribution | About 11.5 L (2 g, healthy volunteers) |
| Metabolism (CYP, transporters) | Not metabolized (excreted unchanged) |
| Active metabolites | None |
| Renal excretion kidney | About 60% in 6 hours and 70% to 80% in 24 hours, unchanged in urine |
| Dialyzability kidney | Not stated in label |
The serum half-life for cefazolin is approximately 1.8 hours following IV administration.
AUC 0-inf = area under the plasma concentration-time curve extrapolated to infinity; t 1/2 = apparent plasma terminal elimination half-life;
Cefazolin is excreted unchanged in the urine.
In the first 6 hours, approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Studies have shown that following intravenous administration of cefazolin to normal volunteers, mean serum concentrations peaked at approximately 185 mcg/mL and were approximately 4 mcg/mL at 8 hours for a 1 gram dose. The serum half-life for cefazolin is approximately 1.8 hours following IV administration.
In a study of constant intravenous infusion with dosages of 3.5 mg/kg for 1 hour (approximately 250 mg) and 1.5 mg/kg the next 2 hours (approximately 100 mg) in healthy volunteers, cefazolin serum concentrations at the third hour were approximately 28 mcg/mL. Plasma pharmacokinetic parameters of cefazolin in healthy volunteers (N=12) following a single 15-minute IV infusion of 2 grams of Cefazolin for Injection and Dextrose Injection are summarized in Table 7.
Table 7: Mean (Standard Deviation) Plasma Pharmacokinetic Parameters of Cefazolin in Healthy Volunteers Dosage of Cefazolin for Injection and Dextrose Injection N C max (mcg/mL) T max T max reported as median (range) (h) AUC 0-inf (mcg*h/mL) t 1/2 (h) CL (L/h) V z (L) Single 2 grams Dose as a 15-Minute IV Infusion 12 280.9 (45.9) 0.25 (0.25-0.33) 509.9 (89.3) 2.01 (0.28) 4.03 (0.68) 11.50 (1.53) N= number of subjects observed; C max = maximum plasma concentration; T max = time to maximum plasma concentration; AUC 0-inf = area under the plasma concentration-time curve extrapolated to infinity; t 1/2 = apparent plasma terminal elimination half-life; CL = total clearance; V z = volume of distribution Model derived plasma pharmacokinetic parameters of cefazolin in adult patients weighing 120 kg or greater (N=12) following a single 30-minute IV infusion of 3 grams of Cefazolin for Injection and Dextrose Injection are summarized in Table 8. Table 8: Mean (Standard Deviation) Model Derived Plasma Pharmacokinetic Parameters of Cefazolin in Adult Patients Weighing ≥ 120 kg Dosage of Cefazolin for Injection and Dextrose Injection N C max (mcg/mL) T max (h) AUC 0--inf (mcg*h/mL) t 1/2 (h) CL (L/h) Vz (L) Single 3 grams Dose as a 30-Minute IV Infusion 12 197.7 (46.6) 0.5 598.6 (206.6) 2.36 (0.687) 5.52 (1.72) 17.51 (3.63) * T max reported based on infusion duration N= number of subjects observed; C max = maximum plasma concentration; T max = time to maximum plasma concentration; AUC 0-inf = area under the plasma concentration-time curve extrapolated to infinity; t 1/2 = apparent plasma terminal elimination half-life; CL = total clearance; V z = volume of distribution Studies in patients hospitalized with infections indicate that cefazolin mean peak serum concentrations were approximately equivalent to those seen in healthy volunteers.
Bile concentrations in patients without obstructive biliary disease can reach or exceed serum concentrations by up to five times; however, in patients with obstructive biliary disease, bile concentrations of cefazolin are considerably lower than serum concentrations (less than 1.0 mcg/mL). In synovial fluid, the cefazolin concentration becomes comparable to that reached in serum at about 4 hours after drug administration.
Studies of cord blood show prompt transfer of cefazolin across the placenta. Cefazolin is present in very low concentrations in the milk of nursing mothers. Cefazolin is excreted unchanged in the urine. In the first 6 hours, approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours.
Specific Populations Pediatric Patients for Perioperative Prophylaxis A simulation based on pharmacokinetic data from healthy adults (n=24), pediatric patients aged 10 to 17 years (n=26: Study 1 [see Adverse Reactions (6.1)]), and pediatric patients aged 10 to 12 years (n=12: Study 2 [see Adverse Reactions (6.1)] indicate that the administration of a 1 gram cefazolin dose for pediatric patients weighing less than 50 kg and a 2 gram cefazolin dose for those weighing 50 kg or greater will provide comparable exposures between pediatric patients aged 10 to 17 years and healthy adults receiving 2 grams Cefazolin for Injection and Dextrose Injection [see Dosage and Administration (2.2 and 2.3) and Use in Specific Populations (8.4)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Cefazolin 1 g Vial | ₱15.23–₱285.00Reference ₱16.53 | per vial | DPRI procurement range |
| Cefazolin 500 mg Vial | ₱28.53–₱29.78Reference ₱28.53 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Cefazolin (as sodium salt) |
| PNF listing | Inj.: 500 mg and 1 g vial (IM, IV) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Cefazolin Sodium · B. Braun Medical Inc. [US FDA-approved label, version 31, March 10, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f8f038-c204-4dab-80d7-6f7ac41ddbec
- U.S. Food and Drug Administration. Cefazolin · WG Critical Care, LLC [US FDA-approved label, version 6, February 27, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f3a9248-a354-4c77-bf5b-9eed38f00219
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- B. Braun Medical Inc. (2025). Cefazolin for injection USP and dextrose injection USP, DUPLEX container (cefazolin) [Prescribing information; US FDA-approved label, NDA050779, set ID 17f8f038-c204-4dab-80d7-6f7ac41ddbec, version effective March 10, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f8f038-c204-4dab-80d7-6f7ac41ddbec
- WG Critical Care, LLC. (2026). Cefazolin for injection (cefazolin; 2 g and 3 g single-dose vials, perioperative prophylaxis) [Prescribing information; alternate label on this page; US FDA-approved label, NDA211413, set ID 4f3a9248-a354-4c77-bf5b-9eed38f00219, version effective February 27, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f3a9248-a354-4c77-bf5b-9eed38f00219
- Tsai, Y. V., Soto, C., Crawford, G., & Dzintars, K. (2025). Important antimicrobial dosing considerations for transitions of care: Focus on thrice-weekly dosing in hemodialysis. American Journal of Health-System Pharmacy, 82(4), 203–210. https://doi.org/10.1093/ajhp/zxae259
- Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .
US label: 2 g and 3 g vials (perioperative prophylaxis)
Indications and usage (US label) US FDA label
1 INDICATIONS AND USAGE Cefazolin for Injection is a cephalosporin antibacterial indicated for perioperative prophylaxis in adult patients (1.1). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and other antibacterial drugs, Cefazolin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria (1.2). 1.1 Perioperative Prophylaxis Cefazolin for Injection is indicated for perioperative prophylaxis in adult patients [see Dosage and Administration (2.1, 2.2, 2.3).
The perioperative use of Cefazolin for Injection is indicated in adult surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for Injection preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and other antibacterial drugs, Cefazolin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
- Cefazolin for Injection, 2 grams/vial: • For intravenous infusion (2.1)
- • For intravenous bolus injection (2.1)
- • Not for intramuscular administration (2.1)
- Cefazolin for Injection, 3 grams/vial: • For intravenous infusion only (2.1)
- • Not for intravenous bolus injection administration or intramuscular administration (2.1)
- Table 1: Recommended Dosage for Perioperative Prophylaxis in Adults with CLcr Equal to 55 mL/min or Greater (2.2)
- Dose administered ½ hour to 1 hour prior to the start of surgery Additional dose during lengthy operative procedures (e.g., 2 hours or more) Dose for 24 hours postoperatively 1 gram (g) to 2 g 500 mg to 1 g 500 mg to 1 g every 6 hours to 8 hours • See full prescribing information for preparation and administration instructions. (2.3)
2.1 Important Administration Instructions
2.1 Important Administration Instructions
- Cefazolin for Injection, 2 grams/vial: Cefazolin for Injection, 2 grams/vial, is for intravenous infusion or intravenous bolus injection in adult patients [see Dosage and Administration (2.2 and 2.3)]. Not for intramuscular administration.
- Cefazolin for Injection, 3 grams/vial: Cefazolin for Injection, 3 grams/vial, is for intravenous infusion only in adult patients [see Dosage and Administration (2.2 and 2.3)]. Cefazolin for Injection, 3 grams/vial is not for intravenous bolus injection or intramuscular administration [see Dosage and Administration (2.3)].
2.2 Recommended Dosage for Perioperative Prophylaxis Use in Adults
2.2 Recommended Dosage for Perioperative Prophylaxis Use in Adults Recommended Dosage for Perioperative Prophylaxis in Adults with Creatinine Clearance (CLcr) Equal to 55 mL/min or Greater To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended dosages are described in Table 1 below. Administration instructions are as follows:
- Cefazolin for Injection, 2 grams/vial is for intravenous infusion or intravenous bolus injection in adult patients [see Dosage and Administration (2.3)].
- Cefazolin for Injection, 3 grams/vial is only for intravenous infusion in adult patients.
- Cefazolin for Injection, 3 grams/vial is not for intravenous bolus injection in adult patients [see Dosage and Administration (2.3)].
- Cefazolin for Injection 2 grams/vial and 3 grams/vial are not for intramuscular injection. Table 1: Recommended Dosage for Perioperative Prophylaxis in Adults with CLcr Equal to 55 mL/min or Greater Dose administered ½ hour to 1 hour prior to the start of surgery Additional dose during lengthy operative procedures (e.g., 2 hours or more) Dose for 24 hours postoperatively 1 gram (g) to 2 g 500 mg to 1 g 500 mg to 1 g every 6 hours to 8 hours It is important that (i) the preoperative dose be given just prior (1/2 hour to 1 hour) to the start of surgery so that adequate antibacterial concentrations are present in the serum and tissues at the time of initial surgical incision and (ii) Cefazolin for Injection be administered, if necessary, at appropriate intervals during surgery to provide sufficient concentrations of the antibacterial drug at the anticipated moments of greatest exposure to infective organisms. The perioperative prophylactic administration of Cefazolin for Injection should usually be discontinued within a 24-hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection may be continued for 3 to 5 days following the completion of surgery.
2.3 Preparation of Cefazolin for Injection
2.3 Preparation of Cefazolin for Injection Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulate matter is evident in reconstituted fluids, the drug solutions should be discarded. Reconstituted solutions may range in color from pale yellow to yellow.
Reconstitution and Dilution Intravenous Bolus Injection Administration (2 g vial only) For preparation of intravenous bolus injection (2 grams/vial only) use the following steps:
- Reconstitute Cefazolin for Injection, 2 grams/vial single-dose vials with Sterile Water for Injection according to Table 2 below. Shake well until dissolved.
- Further dilute vials with an additional 11 mL Sterile Water for Injection and shake well.
- Inject the solution intravenously slowly, directly, or through tubing for patients receiving parenteral fluids as follows: a For 1 g dose, inject the solution intravenously slowly over 3 to 5 minutes and b For 2 g dose, inject the solution intravenously slowly over 7 to 11 minutes Table 2: Volume and Concentration for Intravenous Bolus Injection Reconstitution (2 g vial only) Cefazolin for Injection Vial Contents Amount of Sterile Water for Injection for Reconstitution Approximate Reconstituted Concentration Approximate Available Volume 2 grams 5.5 mL 333 mg/mL 6.6 mL Pain associated with intravenous bolus administration has been reported with Cefazolin for Injection. Intermittent or Continuous Intravenous Infusion For intermittent or continuous intravenous infusion, reconstitute Cefazolin for Injection single-dose vials with Sterile Water for Injection according to Table 3 below and shake well. After reconstitution further dilute according to Table 3 using the following diluents: For intermittent or continuous infusion: Dilute reconstituted Cefazolin for Injection in one of the following solutions:
- 0.9% Sodium Chloride Injection, USP
- 5% Dextrose Injection, USP Discard unused portion. Table 3: Volumes for Reconstitution and Dilution and Final Concentrations for Intermittent or Continuous Intravenous Infusion Cefazolin for Injection Vial Contents Amount of Sterile Water for Injection for Reconstitution Approximate Reconstituted Concentrations Recommended Diluent Volume Approximate Final Concentrations 2 grams 5 mL 317 mg/mL 50 mL 40 mg/mL 100 mL 20 mg/mL 3 grams 7.5 mL 319 mg/mL 100 mL 30 mg/mL Storage of Reconstituted and Diluted Solutions When reconstituted or diluted according to the instructions above, Cefazolin for Injection is stable for 4 hours at room temperature or for 3 days if stored under refrigeration at 2°C to 8°C (36°F to 46°F).
Kidney dosing: Renal impairment (US label) US FDA label
8.6 Renal Impairment Recommendations for dosage adjustments or intervals for repeat dosing for perioperative prophylaxis in lengthy operative procedures or for postoperative use have not been established for adult patients with impaired renal function (creatinine clearance less than 55 mL/min).
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Cefazolin for Injection, USP: Supplied as 2 grams or 3 grams of cefazolin as a white to cream colored powder in a single-dose vial for reconstitution. For Injection: 2 grams or 3 grams of cefazolin as a powder in a single-dose vial for reconstitution. (3)
- • Hypersensitivity Reactions: Cross-hypersensitivity may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction occurs, discontinue the drug. (5.1)
- • Clostridioides difficile -Associated Diarrhea (CDAD): May range from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. (5.3)
- • Prothrombin Activity: May be associated with a fall in prothrombin activity. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5)
5.1 Hypersensitivity Reactions to Cefazolin, Cephalosporins, Penicillins, or Other…
5.1 Hypersensitivity Reactions to Cefazolin, Cephalosporins, Penicillins, or Other Beta-lactams Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before therapy with Cefazolin for Injection is instituted, careful inquiry should be made to determine whether the patient has had previous immediate hypersensitivity reactions to cefazolin, cephalosporins, penicillins, or carbapenems.
Exercise caution if this product is to be given to penicillin-sensitive patients because cross-hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to Cefazolin for Injection occurs, discontinue the drug.
5.2 Seizures in Patients with Renal Impairment
5.2 Seizures in Patients with Renal Impairment Seizures may occur with the administration of Cefazolin for Injection, particularly in patients with renal impairment [see Use in Specific Populations (8.6)]. Discontinue Cefazolin for Injection if seizures occur. Anticonvulsant therapy should be continued in patients with known seizure disorders.
5.3 Clostridioides difficile
5.3 Clostridioides difficile -Associated Diarrhea Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefazolin for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
5.4 Risk of Development of Drug-resistant Bacteria Prescribing Cefazolin
5.4 Risk of Development of Drug-resistant Bacteria Prescribing Cefazolin for Injection in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. As with other antimicrobials, prolonged use of Cefazolin for Injection may result in overgrowth of nonsusceptible microorganisms.
Repeated evaluation of the patient's condition is essential. Should superinfection occur during therapy, appropriate measures should be taken.
5.5 Prothrombin Activity Cefazolin
5.5 Prothrombin Activity Cefazolin for Injection may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy.
Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated.
5.6 Drug/Laboratory Test Interactions Urinary Glucose
5.6 Drug/Laboratory Test Interactions Urinary Glucose The administration of cefazolin may result in a false-positive reaction with glucose in the urine when using glucose tests based on Benedict’s copper reduction reaction that determine the amount of reducing substances like glucose in the urine. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.
Coombs’ Test Positive direct Coombs' tests have been reported during treatment with cefazolin. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibacterial drugs before parturition, it should be recognized that a positive Coombs' test may be due to the drug.
The following serious adverse reactions to cefazolin for injection are described below and elsewhere in the labeling:
- Hypersensitivity Reactions to Cefazolin, Cephalosporins, Penicillins, or Other Beta-lactams [see Warnings and Precautions (5.1)]
- Seizures in Patients with Renal Impairment [see Warnings and Precautions (5.2)]
- Clostridioides difficile -Associated Diarrhea [see Warnings and Precautions (5.3)] Adult Patients: Most common adverse reactions: gastrointestinal (nausea, vomiting, diarrhea), and allergic reactions (anaphylaxis, urticaria, skin rash). (6) To report SUSPECTED ADVERSE REACTIONS, contact WG Critical Care, LLC at 1-866-562-4708 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The following adverse reactions were reported from clinical trials: Gastrointestinal: Diarrhea, oral candidiasis (oral thrush), mouth ulcers, vomiting, nausea, stomach cramps, epigastric pain, heartburn, flatus, anorexia and pseudomembranous colitis.
Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment [see Warnings and Precautions (5.3)]. Allergic: Anaphylaxis, eosinophilia, urticaria, itching, drug fever, skin rash, Stevens-Johnson syndrome. Hematologic: Neutropenia, leukopenia, thrombocytopenia, thrombocythemia. Hepatic: Transient rise in serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), and alkaline phosphatase levels has been observed.
Reports of hepatitis have been received. Renal: Reports of increased BUN and creatinine levels, as well as renal failure, have been received. Local Reactions: Instances of phlebitis have been reported at site of injection. Some induration has occurred. Other Reactions: Pruritus (including genital, vulvar and anal pruritus, genital moniliasis, and vaginitis).
Dizziness, fainting, lightheadedness, confusion, weakness, tiredness, hypotension, somnolence and headache.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of cefazolin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Immune system disorders: Serum sickness-like reaction Renal and urinary disorders: Acute tubulointerstitial nephritis (ATIN) Skin and subcutaneous tissue disorders: Acute generalized exanthematous pustulosis (AGEP)
6.3 Cephalosporin-class Adverse Reactions
6.3 Cephalosporin-class Adverse Reactions In addition to the adverse reactions listed above that have been observed in patients treated with cefazolin, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterials: Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal impairment, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, a fall in prothrombin activity, hepatic impairment including cholestasis, and pancytopenia.
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of Cefazolin for Injection for perioperative prophylaxis have not been established for pediatric patients.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Studies have shown that following intravenous administration of cefazolin to normal volunteers, mean serum concentrations peaked at approximately 185 mcg/mL and were approximately 4 mcg/mL at 8 hours for a 1 gram dose. In a study of constant intravenous infusion with dosages of 3.5 mg/kg for 1 hour (approximately 250 mg) and 1.5 mg/kg the next 2 hours (approximately 100 mg) in healthy volunteers, cefazolin serum concentrations at the third hour were approximately 28 mcg/mL.
Plasma pharmacokinetic parameters of cefazolin in healthy volunteers (N=12) following a single 15-minute IV infusion of 2 grams of Cefazolin for Injection are summarized in Table 4. Table 4: Mean (Standard Deviation) Plasma Pharmacokinetic Parameters of Cefazolin in Healthy Volunteers N Cmax (mcg/mL) Tmax* (h) AUC0-inf (mcg*h/mL) t1/2 (h) CL (L/h) Vz (L) Single 2 grams Dose as a 15-Minute IV Infusion 12 280.9 (45.9) 0.25 (0.25-0.33) 509.9 (89.3) 2.01 (0.28) 4.03 (0.68) 11.50 (1.53) *Tmax reported as median (range) N= number of subjects observed; Cmax = maximum plasma concentration; Tmax = time to maximum plasma concentration; AUC0-inf = area under the plasma concentration-time curve extrapolated to infinity; t1/2 = apparent plasma terminal elimination half-life; CL = total clearance; Vz = volume of distribution Studies in patients hospitalized with infections indicate that cefazolin produces mean peak serum concentrations approximately equivalent to those seen in normal volunteers.
Distribution Bile concentrations in patients without obstructive biliary disease can reach or exceed serum concentrations by up to five times; however, in patients with obstructive biliary disease, bile concentrations of cefazolin are considerably lower than serum concentrations (less than 1 mcg/mL). In synovial fluid, the cefazolin concentration becomes comparable to that reached in serum at about 4 hours after drug administration.
Studies of cord blood show prompt transfer of cefazolin across the placenta. Cefazolin is present in very low concentrations in the milk of nursing mothers. Elimination The serum half-life for cefazolin is approximately 1.8 hours following IV administration. Excretion Cefazolin is excreted unchanged in the urine. In the first 6 hours approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours.

